Micro labs to offer mucolytic solution for respiratory care with its recently launched Pulmucus range - Video

With an aim to strengthen its presence in the field of respiratory care, Microlabs has recently brought out the Pulmucus range- consisting of Pulmucus-600 and Pulmucus AB for symptom relief in respiratory infections, chronic obstructive pulmonary disease and bronchial asthma in India.

Pulmucus Range is available in two formulations: Pulmucus-600, containing Acetylcysteine 600 mg in an effervescent tablet form, and Pulmucus-AB, combining Acetylcysteine 600 mg with Acebrophylline 100 mg in the form of tablets.

Pulmucus-600 could be clinically suited for patients with acute and chronic bronchitis, COPD, and chronic sinusitis, otitis media with effusion, offering a patient convenient option in the form of effervescent tablets. While Pulmucus-AB provides added bronchodilatory benefits, making it ideal for asthma and COPD patients dealing with bronchospasm and breathlessness.

Additionally, Pulmucus-AB, with Acebrophylline, offers bronchodilation with fewer cardiovascular side effects compared to Theophylline.

Acetylcysteine is a mucolytic agent, helps in reducing viscosity of bronchial mucus & has antioxidant properties. Acebrophylline has bronchodilating, muco-regulating, and anti-inflammatory properties that help in airway obstruction. This combination helps in bringing down the mucous hypersecretion and inflammatory response associated with Asthma & COPD.

Managing mucus hypersecretion is vital in both outpatient and emergency respiratory clinical settings. Studies show N-Acetylcysteine not only improves lung function (PEFR, FEV1) but also helps prevent hospital admissions and reduces the risk of re-hospitalisation in COPD patients by up to 30%.

Mr. Girish Mahadev, Vice President- Sales and Marketing Microlabs said “With the introduction of Pulmucus, we’re taking a proactive step in addressing one of the often-overlooked aspects of chronic respiratory diseases—excess mucus. In a country where air pollution significantly adds to the respiratory disease burden, Pulmucus offers relief with mucolytic, antibacterial, antioxidant, and anti-inflammatory benefits through proven molecules like N-Acetylcysteine and Acebrophylline. With Pulmucus Range, we endeavor to dissolve mucus and restore comfort and quality of life among people suffering from related respiratory disease conditions.”

Micro Labs Limited is an Indian pharmaceutical company with its headquarters in Bangalore, India. The company specializes in the areas of cardiac diseases, diabetes, anti-bacterial compounds, antiseptics, vitamins and pain management.